Latest Videos Archives

Updates in Advanced Urothelial Carcinoma

Posted by Neda Hashemi, MD | Nov 2024

Neda Hashemi, MD, presents emerging systemic therapies for advanced bladder cancer, focusing on the transformative shifts since 2023. She highlights the pivotal role of recent ESMO findings in reshaping treatment paradigms, underscoring the shift from conventional platinum-based chemotherapy to more advanced immunotherapy-based approaches.

In this 18-minute presentation, Hashmi elaborates on the importance of the EV-302 trial, noting that these advances mark a turning point in treating metastatic bladder cancer. The CheckMate 901 study, though overshadowed by EV-302, also reveals promising results. Response rates for these patients suggest potential breakthroughs in disease management.

Hashemi acknowledges the complexity of managing treatment-related toxicities and emphasizes the importance of developing strategies to manage side effects effectively. Hashmi also touches on accessibility challenges outside the US, stressing the need for personalized approaches based on regional availability.

Novel Ways of Targeting the Androgen Receptor

Posted by Daniel P. Petrylak, MD | Nov 2024

Daniel P. Petrylak, MD, explores novel approaches for targeting the androgen receptor (AR) in prostate cancer, highlighting that around 90% of prostate cancer specimens express the androgen receptor, which persists through castrate resistance.

In this 7-minute talk, Dr. Petrylak focuses on targeting the AR ligand-binding domain with molecules known as proteolysis-targeting chimeras (PROTACs). Laboratory findings reveal that PROTACs can degrade AR variants resistant to traditional therapies like enzalutamide, showing efficacy against androgen gene amplification mutations.

He shares that ARV-110, a PROTAC developed for clinical use, showed promise in phase 1 trials with castration-resistant prostate cancer patients. However, due to significant side effects, the ARV-110 trials were abandoned in favor of a newer compound, ARV-766. While ARV-110 has demonstrated efficacy in castration-resistant prostate cancer, ARV-766 offers a broader range of AR degradation with improved patient tolerance, making it the preferred candidate for continued clinical evaluation.

LUGPA Talk: Healthcare Landscape, Reimbursement

Posted by Jeffrey M. Spier, MD | Nov 2024

Jeffrey M. Spier, MD, focuses on reimbursement, healthcare policy, and the role of advocacy in the current urology healthcare landscape. In this 10-minute presentation, Spier highlights LUGPA, which represents independent urology practices, promoting best practices, business acumen in urology, and policy advocacy.

Spier emphasizes the importance of urologists and healthcare professionals engaging in legislative advocacy to address issues such as reimbursement cuts, regulatory burdens, and rising operational costs. He notes that healthcare consolidation can negatively impact patient care and stresses the need for reform, particularly in areas like the Medicare fee schedule.

Spear advocates for unity within the urology community. He remains optimistic, calling for collective efforts to secure better outcomes for both physicians and patients while urging professionals to engage at local and national levels to make meaningful change.

Non-surgical Modalities for Pelvic Floor Disorders

Posted by Oscar A. Aguirre, MD | Nov 2024

Oscar A. Aguirre, MD, discusses managing female stress urinary incontinence and related pelvic floor issues, including non-surgical treatments. In this 11-minute talk, Aguirre notes a shift away from surgeries as non-invasive options have proven effective in alleviating urinary symptoms.

Dr. Aguirre began using laser treatments for vaginal tightening in 2013, which unexpectedly improved patients’ sexual function, lubrication, and incontinence. Over time, these experiences revealed the utility of various non-surgical options, including radiofrequency and platelet-rich plasma (PRP) therapies, for enhancing both sexual health and urinary symptoms. He emphasizes that these treatments, though not FDA-approved for incontinence, have shown promising results in improving symptoms without invasive intervention.

MRI in Localized and Recurrent Prostate Cancer

Posted by Baris Turkbey, MD | Nov 2024

In this 9-minute presentation, Baris Turkbey, MD, discusses the role of MRI in diagnosing localized and recurrent prostate cancer. He begins with a clinical case illustrating how MRI-guided biopsy can identify significant cancers missed by traditional systematic approaches.

Dr. Turkbey highlights the importance of standardized imaging practices, such as PI-RADS guidelines, which improve consistency in image acquisition and interpretation. He emphasizes that effective use of MRI involves coordination among radiologists, urologists, and pathologists, making quality control critical across all stages.

In recurrent prostate cancer, Dr. Turkbey stresses that MRI proves especially valuable in conjunction with PSMA PET imaging, aiding in localizing biochemical recurrence foci and enabling early curative interventions. He discusses updated PI-RR guidelines for interpreting MRI in post-treatment settings, recommending specific imaging sequences to improve detection in challenging scenarios. He demonstrates successful applications of MRI in detecting recurrence after surgery or radiotherapy, underscoring its diagnostic precision.